This site is intended for healthcare professionals

Quviviq is granted EU approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder.

Read time: 1 mins
Published:11th May 2022

Idorsia Ltd announced the European Commission (EC) has granted marketing authorization for Quviviq (daridorexant) for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.

Chronic insomnia disorder is one of the most prevalent sleep disorders in Europe, affecting between 6%-12% of the adult population, and impacting both physical and mental health.

With this approval, Quviviq becomes the first dual orexin receptor antagonist (DORA) in the European Union (EU) for the treatment of insomnia. Rather than inducing sleep through broad inhibition of brain activity, Quviviq blocks only the activation of orexin receptors. Consequently, Quviviq decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages.

Condition: Sleeping Disorders
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.